We performed a multicentre, retrospective, international cohort study of patients with TRCC treated with cabozantinib...24 were evaluable for response and were included in this study (21 with TFE3 and 3 with TFEB translocations)...The proportion of patients who achieved an objective response was 16.6%, including 1 complete response and 3 partial responses. For 11 (45.8%) patients, stable disease was the best response....This real-world study provides evidence supporting activity of cabozantinib in TRCC, with more durable responses to therapy...